Company Mission and Market Opportunity - Zomedica aims to bring innovative technology to veterinarians, improving pet care, pet parent satisfaction, and practice profitability[10] - The company estimates a $2.5 billion total annual recurring revenue addressable market, focusing on therapeutic devices and diagnostics[15] - The U S total annual serviceable market is $2.5 Billion, with recurring annual revenue ranging from $650 to $24,000 and per unit capital revenue ranging from $4,500 to $30,000[22] Financial Performance and Growth - Zomedica experienced significant revenue growth, with therapeutic devices growing by approximately 28% and diagnostics growing by approximately 252% in FY23[17, 18] - The company's gross margins are approximately 69%[19] - Total revenue increased from $4.1 million in 2021 to $25.2 million in 2023, a 33% increase from 2022 to 2023[31, 120] Product Portfolio and Innovation - The company's product portfolio includes PulseVet for shock wave therapy, Assisi devices for targeted PEMF therapy, TRUVIEW for digital cytology, TRUFORMA for point-of-care diagnostics, and VetGuardian for pet monitoring[25, 42, 49, 56, 73] - Zomedica plans to launch four to six new assays in 2024, expanding its point-of-care diagnostic solutions[69] Operational Efficiency and Commercial Strategy - Zomedica is focused on achieving operational efficiencies through its two U S manufacturing facilities and integration of Qorvo Biotechnologies' R&D and manufacturing[89, 93] - The company employs a multi-channel sales strategy, including an internal sales force, U S and international distributors, and eCommerce[98] Financial Strength - Zomedica had $90.9 million in liquidity as of March 31, 2024[32]